Certain Common Stock of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024.
January 08, 2024
Share
Certain Common Stock of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024. These Common Stock will be under lockup for 61 days starting from 8-NOV-2023 to 8-JAN-2024.
Details:
Directors and certain executive officers, have agreed that, without the prior written consent of Goldman Sachs & Co. LLC, they will not, or cause or direct any of their affiliates to, during the period ending 60 days after the date of this prospectus supplement, offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise transfer or dispose of any shares of common stock, or any options or warrants to purchase any shares of common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.